Musli Thyropeutics
Slowing Cancer Progression via the Thyroid Gland
Company Overview
Snapshot
Founded in November 2011 by Offer Fabian and Osnat Ashur-Fabian, Musli Thyropeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage and is focused on clinical trials for its cancer treatment.
Business overview
Musli Thyropeutics is a Health Tech & Life Sciences company focused on developing treatments that induce hypofunction of the thyroid gland to slow and inhibit cancer progression. Its core technology aims to enhance the efficacy of chemotherapy and radiotherapy. The company's current research is centered on inducing hypothyroxinemia as an adjunct to conventional therapies for glioblastoma multiforme patients, with safety and efficacy assessments supported by the Tel Aviv Sourasky Medical Center. Musli Thyropeutics operates within the Pharmaceuticals sector, targeting the United States market.
Strategic signal
In November 2016, Musli Thyropeutics initiated a study on the induction of hypothyroxinemia as an adjunct to conventional therapies in glioblastoma multiforme patients. This clinical trial, registered on ClinicalTrials.gov, signals the company's commitment to validating its therapeutic approach through rigorous scientific investigation, which is crucial for advancing novel cancer treatments in the pharmaceutical industry.
Company Intelligence Q&A
- What is Musli Thyropeutics' primary focus?
- Musli Thyropeutics focuses on developing treatments that induce hypofunction of the thyroid gland to slow and inhibit cancer progression and enhance the efficacy of chemotherapy and radiotherapy.
- When was Musli Thyropeutics founded?
- Musli Thyropeutics was founded in November 2011.
- Who are the founders of Musli Thyropeutics?
- The co-founders of Musli Thyropeutics are Offer Fabian, who serves as CEO, and Osnat Ashur-Fabian, who is the CSO.
- What is the current product stage of Musli Thyropeutics?
- Musli Thyropeutics' product is currently in the Clinical Trial stage. This involves a study initiated in November 2016 on the induction of hypothyroxinemia as an adjunct to conventional therapies in glioblastoma multiforme patients, registered on ClinicalTrials.gov.
- What is the status of Musli Thyropeutics?
- Musli Thyropeutics is currently Non Active, having ceased to operate in December 2021.